More on Eli Lilly's (LLY) Q4: Decreased Y/Y revenue tied to loss of patent exclusivity for...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

More on Eli Lilly's (LLY) Q4: Decreased Y/Y revenue tied to loss of patent exclusivity for Zyprexa. Operating expenses up 2% Y/Y, led by fees from health care reform legislation. R&D decreased 6% Y/Y to $1.36B. Reconfirms 2012 EPS guidance of $3.10-$3.20. (PR)